+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report



EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report



Lung Cancer 49(3): 413-415



EGFR mutations have been shown to correlate with the clinical responsiveness to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The detection of EGFR mutations in non-small cell lung cancer (NSCLC) is important from the perspective of targeted anticancer therapy. We report the first case showing that the status of EGFR mutations can be successfully determined in malignant pleural effusion of NSCLC using polymerase chain reaction (PCR) technique, and correlated to the clinical responsiveness to gefitinib, an EGFR-TKI. This case demonstrated the importance of molecular cytology in the era of targeted therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 048845812

Download citation: RISBibTeXText

PMID: 15913841

DOI: 10.1016/j.lungcan.2005.02.016


Related references

Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples. Thoracic Cancer 2018, 2018

Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient. Gene 644: 87-92, 2017

Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting EGFR Mutations in Matched Tumor Tissue, Cell Block, Pleural Effusion and Blood of Lung Cancer Patients With Malignant Pleural Effusion. In Vivo 33(2): 595-603, 2019

Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors. Tumour Biology 39(6): 1010428317706211, 2017

Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation. Journal of International Medical Research 42(5): 1110-1117, 2015

Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature. Oncotarget 8(29): 48521-48524, 2017

RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. European Respiratory Journal 39(3): 677-684, 2012

49P Accuracy of pleural fluid cytology in patients with malignant pleural effusion from non-small-cell lung cancer, pulmonary metastases and pleural mesothelioma. A case-control study. Journal of Thoracic Oncology 11(4 Suppl): S75-S75, 2016

Pleural effusion as a substitute for tumor tissue in detecting EGFR/ALK mutations in non-small cell lung cancer: A systematic review and meta-analysis. Medicine 98(18): E15450, 2019

Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients. Clinical Chemistry and Laboratory Medicine 55(12): 1962-1969, 2017

Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer 65(3): 371-376, 2009

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cellular Oncology 35(3): 189-196, 2013

Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion. Anticancer Research 36(6): 2939-2944, 2017

Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer 60(2): 175-182, 2007

Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. Clinical Lung Cancer 15(5): 379-386, 2015